PVP Labs to Present TAPHALGIN® Tetrapeptide Analgesic Platform at JP Morgan Healthcare Conference 2026
PVP Labs, a biotechnology company advancing next-generation peptide-based therapeutics, today announced its participation in the JP Morgan Healthcare Conference 2026, where the company will engage with institutional investors and strategic partners to present its leading product, TAPHALGIN®, an innovative, non-addictive analgesic platform.
